---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019314"
form_type: "8-K"
ticker: null
cik: "0001106838"
company_name: "Sonnet BioTherapeutics Holdings, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:16:06.366306+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sonnet Q2 cash $3.8M; runway into July/August 2024; pipeline shifts to DPN

## Summary
- Cash $3.8M as of Mar 31, 2024; no debt; expects runway into July 2024, potentially August with cost cuts.
- Q2 R&D expenses $2.2M (down from $3.8M), G&A $1.7M (down from $1.9M) from cost-saving initiatives.
- Received $4.3M net proceeds from NJ NOL sale; entered equity facility with Chardan for capital raise.
- SON-1010 Phase 1 data published showing safety up to 300 ng/kg; SON-080 cleared by DSMB.
- CIPN program placed on hold; targeting diabetic peripheral neuropathy; seeking partnerships for SON-080.

## SEC filing metadata
- accession: 0001493152-24-019314
- form_type: 8-K
- cik: 0001106838
- company_name: Sonnet BioTherapeutics Holdings, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019314
- JSON: https://secwatch.observer/filing/0001493152-24-019314.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019314.txt

## Key facts
- Earnings Releases
  Sonnet BioTherapeutics Holdings, Inc. reported financial results for three months ended March 31, 2024.
  - Period: three months ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm
- Earnings Releases
  Sonnet BioTherapeutics Holdings, Inc. reported financial results for three months and six months ended March 31, 2024.
  - Period: three months and six months ended March 31, 2024
  - Result: reported results
  source text: Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended March 31, 2024 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.